FATENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
FATE THERAPEUTICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.86+0.07 (+3.91%)
Close on Oct 19, 2026
- Market cap
- $223.94M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$0.39 (+26.53%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
FATE THERAPEUTICS INC saw revenue fall 23.4% to $6.49M over the twelve months to Jun 30, 2026. Free cash flow was -$105.62M.
Revenue
$6.49M
-23.4% vs. a year earlier
Operating income
-$133.59M
TTM Q2 2026
Free cash flow
-$105.62M
TTM Q2 2026
EPS, diluted
-$1.05
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $223.94M
- P/E ratio
- –
- Price to sales
- 34.50
- Price to book
- 1.46
- Dividend yield
- –
- Free cash flow yield
- -47.17%
Fundamentals
- Revenue
- $6.49M
- Net income
- -$126.00M
- EPS, diluted
- -$1.05
- Free cash flow
- -$105.62M
- Book value per share
- $1.27
- Diluted shares
- 120M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$6.49M-23.4% YoY
Operating income
-$133.59M
Net income
-$126.00M
EPS, diluted
-$1.05
Free cash flow
-$105.62M
Reported periodTrailing twelve months